T1	Premise 1018 1173	Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).
T2	Premise 1174 1346	There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.
T3	Premise 1347 1422	Nearly 80% of patients reported one or more side effects with either agent.
T4	Premise 1423 1508	No differences in frequency, grade, or range of side effects were seen between drugs.
T5	Claim 1680 1716	both AIs are equally well tolerated.
T6	Claim 1717 1791	There were no significant differences in QOL scores between the two drugs.
R1	Support Arg1:T4 Arg2:T5	
R2	Support Arg1:T2 Arg2:T5	
R3	Support Arg1:T1 Arg2:T5	
R4	Support Arg1:T2 Arg2:T6	
R5	Support Arg1:T1 Arg2:T6	
R6	Partial-Attack Arg1:T3 Arg2:T5	
